UCSF Pediatric Oncology, 505 Parnassus Ave, Box 0106, San Francisco, CA 94143-0106, USA.
J Clin Oncol. 2010 Jan 10;28(2):324-31. doi: 10.1200/JCO.2009.22.5060. Epub 2009 Nov 16.
Children with acute lymphoblastic leukemia (ALL) are often cured, but the therapies they receive may be neurotoxic. Little is known about the incidence and severity of late-occurring neurologic sequelae in ALL survivors. Data were analyzed to determine the incidence of adverse long-term neurologic outcomes and treatment-related risk factors.
We analyzed adverse neurologic outcomes that occurred after diagnosis in 4,151 adult survivors of childhood ALL who participated in the Childhood Cancer Survivor Study (CCSS), a retrospective cohort of 5-year survivors of childhood cancer diagnosed between 1970 and 1986. A randomly selected cohort of the survivors' siblings served as a comparison group. Self-reported auditory-vestibular-visual sensory deficits, focal neurologic dysfunction, seizures, and serious headaches were assessed.
The median age at outcome assessment was 20.2 years for survivors. The median follow-up time to death or last survey since ALL diagnosis was 14.1 years. Of the survivors, 64.5% received cranial radiation and 94% received intrathecal chemotherapy. Compared with the sibling cohort, survivors were at elevated risk for late-onset auditory-vestibular-visual sensory deficits (rate ratio [RR], 1.8; 95% CI, 1.5 to 2.2), coordination problems (RR, 4.1; 95% CI, 3.1 to 5.3), motor problems (RR, 5.0; 95% CI, 3.8 to 6.7), seizures (RR, 4.6; 95% CI, 3.4 to 6.2), and headaches (RR, 1.6; 95% CI, 1.4 to 1.7). In multivariable analysis, relapse was the most influential factor that increased risk of late neurologic complications.
Children treated with regimens that include cranial radiation for ALL and those who suffer a relapse are at increased risk for late-onset neurologic sequelae.
儿童急性淋巴细胞白血病 (ALL) 患者通常可以被治愈,但他们接受的治疗可能具有神经毒性。关于 ALL 幸存者迟发性神经后遗症的发生率和严重程度,目前知之甚少。本研究旨在分析数据,以确定不良长期神经结局的发生率和与治疗相关的危险因素。
我们分析了在参加儿童癌症幸存者研究 (CCSS) 的 4151 例成年 ALL 幸存者中,在诊断后出现的不良神经系统结局。CCSS 是一项回顾性队列研究,纳入了 1970 年至 1986 年期间诊断为儿童癌症的 5 年幸存者。幸存者的随机选择的兄弟姐妹作为对照组。评估了听觉-前庭-视觉感觉缺陷、局灶性神经功能障碍、癫痫发作和严重头痛等自报告的神经系统障碍。
幸存者的结局评估中位年龄为 20.2 岁。从 ALL 诊断到死亡或最后一次调查的中位随访时间为 14.1 年。幸存者中,64.5%接受了颅部放疗,94%接受了鞘内化疗。与兄弟姐妹组相比,幸存者发生迟发性听觉-前庭-视觉感觉缺陷的风险较高(风险比 [RR],1.8;95%可信区间,1.5 至 2.2)、协调问题(RR,4.1;95%可信区间,3.1 至 5.3)、运动问题(RR,5.0;95%可信区间,3.8 至 6.7)、癫痫发作(RR,4.6;95%可信区间,3.4 至 6.2)和头痛(RR,1.6;95%可信区间,1.4 至 1.7)。多变量分析显示,复发是增加迟发性神经并发症风险的最主要因素。
接受包含颅部放疗的 ALL 治疗方案和发生复发的儿童,发生迟发性神经后遗症的风险增加。